leadf
logo-loader
viewOpen Orphan PLC

Open Orphan opens walk-in challenge trial sites in London and Manchester to help coronavirus research

The new site at Whitechapel is the first at street level

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) has opened two new walk-in recruitment centres to screen potential volunteers for challenge trials in East London and central Manchester.

The new sites, which are part of a planned expansion of trials in 2021, include a repurposed former coffee shop at the street level of Queen Mary BioEnterprise Innovation Centre (QMB) in Whitechapel, East London.

The QMB centre currently houses subsidiary hVIVO's current 24-bedroom quarantine clinic, but the new site is the first to be located at street level where volunteers can walk straight in for screening.

With the new site, the QMB facility can offer 520 volunteer recruitment visit slots per week. The central Manchester site will have the capacity for 100 visits per week.

Open Orphan has seen a big rise in demand for challenge trials as companies and health bodies search for treatments and vaccines for coronavirus (COVID-19) and also just to understand better how the virus affects people.

In a statement, Cathal Friel, Open Orphan’s executive chairman, said: “The current pandemic has forced many businesses to close and we are able to provide another use for these spaces not currently in use. These spaces presented an opportunity for us to open street-level volunteer recruitment centres quickly and efficiently.

“The number of volunteers required by hVIVO is increasing rapidly in line with the number of studies the company is running, and these two additional centres will allow us to increase our capacity substantially in the year ahead.”

Open Orphan added it is looking for trial volunteers and anyone interested can learn more at: www.flucamp.com/what-is-screening/.

Quick facts: Open Orphan PLC

Price: 28.5 GBX

AIM:ORPH
Market: AIM
Market Cap: £190.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan to become '$1bln firm in very near future' after COVID-19 study...

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC).  This follows a contract received by the company’s subsidiary hVIVO...

2 weeks, 5 days ago

2 min read